top of page
SHAPE Presentations
dr-180108043357-thumbnail.webp
AHA SHAPE Symposium 2017 Dr. Naghavi Presentation
5kloner-180108043246-thumbnail.webp
AHA SHAPE Symposium 2017 Dr. Kloner Presentation
4greenland-180108043143-thumbnail.webp
AHA SHAPE Symposium 2017 Dr. Greenland Presentation
3yen-180108043036-thumbnail.webp
AHA SHAPE Symposium 2017 Dr. Yen Presentation
2slomka-180108042744-thumbnail.webp
AHA SHAPE Symposium 2017 Dr. Slomka Presentation
yqfrfxb7qwo39m6toen0-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vu lplaque1 pasterkamp
mad1uuxsskkir8nfuqlw-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable plaque vulnerable patient
mfswhnjpr3ahzsvoax8m-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable plaque overview
5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable patient talk in poland
5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable patient slides without movies
5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable patient slides with movies
bpjjjkqjygttwobapucq-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable patient mar 04
cpp5sfazstuhymrh0g42-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vulnerable (thrombogenic blood
bruhekbarg7gskc8arr5-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vuln shape aha 2005
ong6ubwbrjq0x2yzitcv-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vuln plaque poster burke
20rxh3kjsuyjnwejc65q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial_slide 25short-
d5hurgbs1w9jnhh9731a-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial_slide25
20rxh3kjsuyjnwejc65q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial_slide25short-
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch2002
mrsiewo9sjsvtf4brkz6-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp symposium31602
y9mlgowptgose5q1ufx2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vpschoenhagen
dzelv2glrcycowb4dqjh-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp meeting orlando2003_new template
y3vajtd9qw06r7t39u1q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vpiii lobby-02
q3qv0cdbtgigvepxourd-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp
afxga6fzqd6f5jl0evnf-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp.org cimit harvard
6wxrmfw0sdkbvhryvvo8-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp texas by yuan
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial - v2 n3- 2002
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial - v2 n2- 2002
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial - v2 n6- 2002
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp watch editorial - v2 n4- 2002
mrsiewo9sjsvtf4brkz6-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp symposium 3 16-02
lk95kaeorr2v01lljt08-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp schoenhagen
jqnxzskctqdrdwauap6w-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp slides
urunil5aspu0uuoaxfme-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp presentation jar 3 29 03
rvfmfdsrg0vtc0pccezg-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp paper 7 pics (aeha logo)
q9edmehvrmmh1ghh4ypl-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp lightlab kolstad (industry)
yvuwde82qmwpgu7akdpn-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vp 2002 talk show copy galis
qqcykfpcq920odj2fflk-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Voorbeeld3 dhisto
ihvlgsq8rt2rnquoub7g-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Volcano avi
cnrd2utrdmfwgqdsu2to-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Visualization of atherosclerotic vulnerable plaque
pfa8ymtqr7yc7nyfqg2g-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vogel endothelial function cv es
14d2arihrra6tudqqugz-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Virmani
ojwxm3rj1qcdgbnhita2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vascular interventions
umclsflsth6se5pty4dx-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Virella
ojwxm3rj1qcdgbnhita2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Vascular interventions atalar- johns hopkins
lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
V2n31
5lu1ficcsrs8mw7kg7ag-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Updated power point presentation of the vulnerable patient manuscript
abh3dfroqyidqm4j86hm-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Toyotaka
coaiqeqqqugfxiovwukg-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Transgenic cetp dahl salt sensitive (tg53) rat model
Towards immune modulation vp
Tlr4 circulation
Towards immune modulation vp 16 11 gkh
Tissue contrast
Thermographya novel approach for the identification of vp
Thermographya novel approach for the identification of vp
Thermographya novel approach for the identification of vp
Thermo elastography
Thermo elastography
Thermal hetrogeneity clinical syndrome 2
The fat fed apoe ko mouse- chris jackson- u of bristol
fducisgzqjc1kcjuwymv-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
The prevalence of inflammatory cells in non ruptured atherosclerotic plaques
The prev of inf cells in nonrupt a. plaque pasterkamp- part 2
The new design basket catheter system
The entire poster presentation of vp symposium acc 2003
n12nytesxkpwygo7eghl-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a
Tct recognition of vulnerable plaque guidelines
Tct fat poster-title
Tct mri 2001
Tct arrow pics, landscape
Taylor.aeha cac imt progression talk.1
Tawakol
Symposium jang
Stroes
Strains vp
suoyjwv0tmeuxuqecmc0-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Stephanes talk aeha
Stenosis vs risk
Stenosis severity and risk benefit
Stein cimt for shape 11-05
Stefanadis
Statins are associated
Statin periomort
Spio mri studies by dr naghavi-presented to ge-amersham
dkly80yztg2gq6tzeoqo-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Spio mri studies by dr naghavi
Spio mri studies by dr naghavi - presented to ge-amersham
Spio mri studies by dr naghavi - amersham oct 2003 - part 1
Spio cytokinejan28
Spio mri studies by dr naghavi - amersham oct 2003 - part2
Spio cytokinejan28-2
pl9gjgfbqzcq2dfcux6b-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Spio uptake by macrophages
yamqq8epqsgjju76bifn-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Spio photo
Spectroscopic fiber optic catheter tania - aha 2001
Spatial encoding part_2
Spect ct -dan berman
Slides 25 28
Slides 29 38
Slides naqvi
Slides 21 24
Slides 9 20
Slides 20 37 -vulnerable patient with movies
Slides 1 20 -vulnerable patient with movies
nqzawfeuqba7ozge9ymw-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Slides 1 8
Slides2938
Slides2528
Slides920
Slides2124
Slides18
Slagerperspective
Slide shows of uptake of spio by macrophages and monocytes10
Slager1
Silvio flu
Shuzou
Silvio sept 24
Shoenhagen
Shape a-thon clinton
Shape symposium slide presentation
Shape aha 2005
Seferovic
Shah vaccine
Schwartz debate aha 2002
Scd
Saloner presentation
Rumberger vp discussion 11 03
Rumberger 2nd vp symposium 3 6 04
Rumberger
Rumberg 4
Rumberg3
Revisiting the basics culprit vs non culprit
Revisiting the basics culprit vs non culprit
qfltloektdqhtrqoatix-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Rumberg1
Ricenano
Resp infection of apoe ko mice and plaque inflammation
Rumberg2
Research findings
Recent results and findings.
Progress with the a 3 fr nir fiber optic catheter
Pulse sequences gradient echo
Project introduction
Preset3
Presentation1
Ppt for adelson sketch
eh85igzxryys4hmm6hmt-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Positive remodeling slides for ralph
Positive remodeling for ralph
Polymophism in the promoter
Plaque petct
Pharmacologic treatment of vulnerable plaque
Plaque rupture definition
Plaque severity and coronary occlusion
Plaque inflammation july 2
Plaque inflammation in atherosclerotic rabbits
Plaque inflammation in atherosclerotic rabbits
Patrick updown
Plaque characterization with oct
agcvnmajrtaldu4hwgkv-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818
Phil graham new
Peter libby, md
Periadventitial fat
Percutaneouse
Pbg vp mar02_final
Percutaneous coronary intervention by hossein
Percutaneouse coronary intervention
Pasterkamp1
Pasterkamp2
Pasterkamp
Pandemic of cvd atlanta
Out of hospital
Pancoronary therapy with ipdd
Out of hospital sudden cardiac death (scd) declining or escalating
Out of hospital sudden cardiac death(scd)
Out of hospital 2

Date: Mon Jan 8 4:33

Date: Mon Jan 8 4:32

Date: Mon Jan 8 4:31

Date: Mon Jan 8 4:30

Date: Mon Jan 8 4:27

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

bottom of page